CO7350624A2 - Inhibidores de la tirosina-quinasa de bruton - Google Patents
Inhibidores de la tirosina-quinasa de brutonInfo
- Publication number
- CO7350624A2 CO7350624A2 CO15098489A CO15098489A CO7350624A2 CO 7350624 A2 CO7350624 A2 CO 7350624A2 CO 15098489 A CO15098489 A CO 15098489A CO 15098489 A CO15098489 A CO 15098489A CO 7350624 A2 CO7350624 A2 CO 7350624A2
- Authority
- CO
- Colombia
- Prior art keywords
- tyrosine kinase
- compounds
- bruton tyrosine
- conditions
- kinase inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Abstract
Se describen en la presente compuestos que forman enlacescovalentes con tirosina quinasa de Bruton (BTK). Se describen losmétodos para la preparación de los compuestos. Se describentambién composiciones farmacéuticas que incluyen los compuestos.Se describen los métodos de uso de los inhibidores de BTK, solos oen combinación con otros agentes terapéuticos, para el tratamientode enfermedades o condiciones autoinmunes, enfermedades ocondiciones heteroinmunes, cáncer, que incluye linfoma yenfermedades o condiciones inflamatorias.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261721920P | 2012-11-02 | 2012-11-02 | |
US201361772028P | 2013-03-04 | 2013-03-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO7350624A2 true CO7350624A2 (es) | 2015-08-10 |
Family
ID=49596360
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO15098489A CO7350624A2 (es) | 2012-11-02 | 2015-04-29 | Inhibidores de la tirosina-quinasa de bruton |
Country Status (27)
Country | Link |
---|---|
US (4) | US20150291554A1 (es) |
EP (1) | EP2914586B1 (es) |
JP (1) | JP6178861B2 (es) |
KR (1) | KR101668574B1 (es) |
CN (1) | CN105008344B (es) |
AP (1) | AP2015008381A0 (es) |
AU (1) | AU2013340345B2 (es) |
BR (1) | BR112015009624A2 (es) |
CA (1) | CA2888960C (es) |
CL (1) | CL2015001168A1 (es) |
CO (1) | CO7350624A2 (es) |
CR (1) | CR20150228A (es) |
DO (1) | DOP2015000100A (es) |
EA (1) | EA201500393A1 (es) |
ES (1) | ES2625944T3 (es) |
GE (1) | GEP201606597B (es) |
HK (1) | HK1211293A1 (es) |
IL (1) | IL238571A0 (es) |
MD (1) | MD20150035A2 (es) |
MX (1) | MX2015005422A (es) |
NI (1) | NI201500059A (es) |
PE (1) | PE20151070A1 (es) |
PH (1) | PH12015500940A1 (es) |
SG (1) | SG11201502893WA (es) |
TN (1) | TN2015000168A1 (es) |
TW (1) | TWI518080B (es) |
WO (1) | WO2014068527A1 (es) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2015001802A (es) | 2012-08-10 | 2015-05-07 | Boehringer Ingelheim Int | Compuestos heteroaromaticos como inhibidores de btk. |
ME03455B (me) | 2012-09-10 | 2020-01-20 | Principia Biopharma Inc | Jedinjenja pirazolopirimidina kao inhibitori kinaze |
CN103848810A (zh) * | 2012-11-30 | 2014-06-11 | 北京赛林泰医药技术有限公司 | 鲁顿酪氨酸激酶抑制剂 |
WO2014151620A1 (en) | 2013-03-14 | 2014-09-25 | Boehringer Ingelheim International Gmbh | 5-thiazolecarboxamide dervatives and their use as btk inhibitors |
HUE058914T2 (hu) * | 2013-03-15 | 2022-09-28 | Janssen Pharmaceutica Nv | Gyógyszer elõállítására szolgáló eljárások és köztitermékek |
WO2014152114A1 (en) | 2013-03-15 | 2014-09-25 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as btk inhibitors |
US9156847B2 (en) * | 2013-03-15 | 2015-10-13 | Janssen Pharmaceutica Nv | Processes and intermediates for preparing a medicament |
CN113413393A (zh) * | 2013-08-19 | 2021-09-21 | 塔里斯生物医药公司 | 多单元药物递送装置和方法 |
AU2014324595B2 (en) * | 2013-09-30 | 2018-12-20 | Beijing Innocare Pharma Tech Co., Ltd | Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease |
JP6486954B2 (ja) * | 2014-01-29 | 2019-03-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Btk阻害剤としてのピラゾール化合物 |
ES2841248T3 (es) | 2014-02-21 | 2021-07-07 | Principia Biopharma Inc | Sales y forma sólida de un inhibidor de BTK |
WO2015185998A2 (en) * | 2014-04-11 | 2015-12-10 | Acerta Pharma B.V. | Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase |
CN105085474B (zh) | 2014-05-07 | 2018-05-18 | 北京赛林泰医药技术有限公司 | 鲁顿酪氨酸激酶抑制剂 |
GB201410430D0 (en) | 2014-06-11 | 2014-07-23 | Redx Pharma Ltd | Compounds |
WO2016008411A1 (en) * | 2014-07-18 | 2016-01-21 | Beigene, Ltd. | 5-amino-4-carbamoyl-pyrazole compounds as selective and irreversible t790m over wt-egfr kinase inhibitors and use thereof |
WO2016019237A2 (en) * | 2014-07-31 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
CN105884747B (zh) * | 2014-08-28 | 2021-01-05 | 首药控股(北京)有限公司 | 一种制备布鲁顿酪氨酸激酶(btk)激酶抑制剂的制备方法 |
BR112017013022A2 (pt) | 2014-12-18 | 2018-02-27 | Principia Biopharma Inc | métodos para tratar uma doença inflamatória e/ou autoimune aguda num mamífero que a necessite onde a terapia de corticosteróides é utilizada como terapia de primeira ou segunda linha e/ou para tratar uma doença inflamatória e/ou autoimune num mamífero que a necessite, onde a terapia de corticosteróides é utilizada como terapia de manutenção de primeira ou segunda linha e/ou para eliminar ou reduzir dose terapêutica de corticosteróides utilizado no tratamento de uma doença inflamatória e/ou autoimune num mamífero que a necessite, onde a terapia de corticosteróides é utilizada como terapia de manutenção crônica de primeira ou segunda linha e/ou de tratamento de uma doença autoimune e/ou inflamatória num mamífero que a necessite |
WO2016192074A1 (en) * | 2015-06-04 | 2016-12-08 | Merck Sharp & Dohme Corp. | Btk inhibitors |
US20180305350A1 (en) | 2015-06-24 | 2018-10-25 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
EA201890730A1 (ru) | 2015-09-16 | 2018-10-31 | Локсо Онколоджи, Инк. | Производные пиразолопиримидина в качестве ингибиторов btk для лечения злокачественного новообразования |
DK3377484T3 (da) * | 2015-11-17 | 2023-11-27 | Merck Patent Gmbh | Fremgangsmåder til behandling af multipel sklerose under anvendelse af pyrimidin- og pyridinforbindelser med btk- inhiberende aktivitet |
PE20220502A1 (es) | 2015-12-16 | 2022-04-07 | Loxo Oncology Inc | Compuestos utiles como inhibidores de cinasa |
CN108368086B (zh) | 2015-12-16 | 2021-01-08 | 勃林格殷格翰国际有限公司 | 可用于治疗自身免疫疾病的二吡唑基衍生物 |
JP6916185B2 (ja) | 2016-01-13 | 2021-08-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Btk阻害剤としてのイソキノロン類 |
CN107021963A (zh) | 2016-01-29 | 2017-08-08 | 北京诺诚健华医药科技有限公司 | 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用 |
WO2017163078A1 (en) | 2016-03-24 | 2017-09-28 | Mission Therapeutics Limited | 1-cyano-pyrrolidine derivatives as dbu inhibitors |
JP6953445B2 (ja) * | 2016-05-16 | 2021-10-27 | スーチョウ、シノベント、ファーマスーティカルズ、カンパニー、リミテッドSuzhou Sinovent Pharmaceuticals Co., Ltd. | Btk阻害剤としての5−アミノピラゾールカルボキサミド誘導体およびその製造方法および医薬組成物 |
JP7129704B2 (ja) | 2016-06-29 | 2022-09-02 | プリンシピア バイオファーマ インコーポレイテッド | 2-[3-[4-アミノ-3-(2-フルオロ-4-フェノキシ-フェニル)ピラゾロ[3,4-d]ピリミジン-1-イル]ピペリジン-1-カルボニル]-4-メチル-4-[4-(オキセタン-3-イル)ピペラジン-1-イル]ペント-2-エネニトリルの放出調節製剤 |
GB201616511D0 (en) * | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
TWI771327B (zh) * | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
US11590167B2 (en) | 2016-12-03 | 2023-02-28 | Juno Therapeutic, Inc. | Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors |
JP2020536863A (ja) | 2017-10-06 | 2020-12-17 | フォーマ セラピューティクス,インコーポレイテッド | ユビキチン特異的ペプチダーゼ30の阻害 |
CN111212644B (zh) * | 2017-11-10 | 2021-01-15 | 苏州信诺维医药科技有限公司 | 作为btk抑制剂的5-氨基吡唑甲酰胺化合物的无定型固体分散体 |
CN111225669B (zh) * | 2017-11-10 | 2020-12-29 | 苏州信诺维医药科技有限公司 | 作为btk抑制剂的5-氨基吡唑甲酰胺化合物的晶型i |
CN111225912B (zh) * | 2017-11-10 | 2020-11-10 | 苏州信诺维医药科技有限公司 | 作为btk抑制剂的5-氨基吡唑甲酰胺化合物及其制备方法 |
CN108530436B (zh) * | 2018-05-17 | 2020-12-29 | 黄传满 | 一种吡唑类化合物及其制备方法和应用 |
EP4218934A1 (en) | 2018-10-05 | 2023-08-02 | Forma Therapeutics, Inc. | Inhibiting ubiquitin-specific protease 30 (usp30) |
CN114364798A (zh) | 2019-03-21 | 2022-04-15 | 欧恩科斯欧公司 | 用于治疗癌症的Dbait分子与激酶抑制剂的组合 |
WO2020234379A1 (en) * | 2019-05-21 | 2020-11-26 | Janssen Pharmaceutica Nv | Processes and intermediates for preparing a btk inhibitor |
AU2020378630A1 (en) | 2019-11-08 | 2022-05-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
TW202317099A (zh) * | 2020-09-10 | 2023-05-01 | 美商絡速藥業公司 | 用於製備(s)-5-胺基-3-(4-((5-氟-2-甲氧基苯甲醯胺基)甲基)苯基)-1-(1,1,1-三氟丙烷-2-基)-1h-吡唑-4-甲醯胺之方法及中間體 |
WO2022140246A1 (en) | 2020-12-21 | 2022-06-30 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
WO2023284765A1 (zh) * | 2021-07-16 | 2023-01-19 | 深圳市塔吉瑞生物医药有限公司 | 取代的吡唑类化合物及包含该化合物的组合物及其用途 |
TW202342444A (zh) * | 2022-02-04 | 2023-11-01 | 美商理通製藥公司 | 特定化學實體、組合物及方法 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
US6326469B1 (en) | 1994-04-22 | 2001-12-04 | Sugen, Inc. | Megakaryocytic protein tyrosine kinases |
GB9608435D0 (en) * | 1996-04-24 | 1996-06-26 | Celltech Therapeutics Ltd | Chemical compounds |
US7307097B2 (en) * | 2001-09-27 | 2007-12-11 | Smithkline Beechman Corporation | Chemical compounds |
CA2648923A1 (en) | 2006-04-11 | 2007-10-18 | Vertex Pharmaceuticals Incorporated | Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases |
SI2530083T1 (sl) | 2006-09-22 | 2016-09-30 | Pharmacyclics Llc | Inhibitorji Bruton tirozin kinaze |
FR2908409B1 (fr) | 2006-11-10 | 2009-01-09 | Sanofi Aventis Sa | Pyrazoles substituees,compositions les contenant,procede de fabrication et utilisation |
JP2010533715A (ja) * | 2007-07-17 | 2010-10-28 | アムジエン・インコーポレーテツド | 複素環系pkb調節剤 |
AU2009270856B2 (en) * | 2008-07-16 | 2013-07-25 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors |
AU2009273197B2 (en) | 2008-07-24 | 2014-01-16 | Nerviano Medical Sciences S.R.L. | 3,4-diarylpyrazoles as protein kinase inhibitors |
JP5699149B2 (ja) * | 2009-09-04 | 2015-04-08 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Bruton型チロシンキナーゼ阻害薬 |
WO2011159857A1 (en) * | 2010-06-16 | 2011-12-22 | Bristol-Myers Squibb Company | Carboline carboxamide compounds useful as kinase inhibitors |
MX2015001802A (es) * | 2012-08-10 | 2015-05-07 | Boehringer Ingelheim Int | Compuestos heteroaromaticos como inhibidores de btk. |
CN103848810A (zh) * | 2012-11-30 | 2014-06-11 | 北京赛林泰医药技术有限公司 | 鲁顿酪氨酸激酶抑制剂 |
FR3002733B1 (fr) | 2013-03-04 | 2015-08-14 | Servier Lab | Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US10105632B2 (en) | 2014-04-09 | 2018-10-23 | Donaldson Company, Inc. | Self-supporting folded sheet material, filter elements, and methods |
CN105085474B (zh) * | 2014-05-07 | 2018-05-18 | 北京赛林泰医药技术有限公司 | 鲁顿酪氨酸激酶抑制剂 |
-
2013
- 2013-11-01 GE GEAP201313816A patent/GEP201606597B/en unknown
- 2013-11-01 US US14/439,478 patent/US20150291554A1/en not_active Abandoned
- 2013-11-01 CN CN201380065731.8A patent/CN105008344B/zh not_active Expired - Fee Related
- 2013-11-01 EP EP13792494.0A patent/EP2914586B1/en active Active
- 2013-11-01 JP JP2015540256A patent/JP6178861B2/ja not_active Expired - Fee Related
- 2013-11-01 AU AU2013340345A patent/AU2013340345B2/en not_active Ceased
- 2013-11-01 BR BR112015009624A patent/BR112015009624A2/pt active Search and Examination
- 2013-11-01 MD MDA20150035A patent/MD20150035A2/ro not_active Application Discontinuation
- 2013-11-01 WO PCT/IB2013/059846 patent/WO2014068527A1/en active Application Filing
- 2013-11-01 MX MX2015005422A patent/MX2015005422A/es unknown
- 2013-11-01 PE PE2015000569A patent/PE20151070A1/es not_active Application Discontinuation
- 2013-11-01 AP AP2015008381A patent/AP2015008381A0/xx unknown
- 2013-11-01 KR KR1020157014092A patent/KR101668574B1/ko active IP Right Grant
- 2013-11-01 CA CA2888960A patent/CA2888960C/en active Active
- 2013-11-01 EA EA201500393A patent/EA201500393A1/ru unknown
- 2013-11-01 SG SG11201502893WA patent/SG11201502893WA/en unknown
- 2013-11-01 ES ES13792494.0T patent/ES2625944T3/es active Active
- 2013-11-04 TW TW102139984A patent/TWI518080B/zh not_active IP Right Cessation
-
2015
- 2015-04-27 PH PH12015500940A patent/PH12015500940A1/en unknown
- 2015-04-29 CO CO15098489A patent/CO7350624A2/es unknown
- 2015-04-30 TN TNP2015000168A patent/TN2015000168A1/fr unknown
- 2015-04-30 IL IL238571A patent/IL238571A0/en unknown
- 2015-04-30 CR CR20150228A patent/CR20150228A/es unknown
- 2015-04-30 NI NI201500059A patent/NI201500059A/es unknown
- 2015-05-01 DO DO2015000100A patent/DOP2015000100A/es unknown
- 2015-05-04 CL CL2015001168A patent/CL2015001168A1/es unknown
- 2015-12-09 HK HK15112141.6A patent/HK1211293A1/xx unknown
-
2017
- 2017-06-16 US US15/624,969 patent/US10266513B2/en active Active
-
2019
- 2019-03-08 US US16/296,319 patent/US10815213B2/en active Active
-
2020
- 2020-09-18 US US17/025,026 patent/US20210002251A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO7350624A2 (es) | Inhibidores de la tirosina-quinasa de bruton | |
DOP2015000108A (es) | Compuestos de pirrolopirimidina como inhibidores de quinasas | |
CR20160203A (es) | Inhibidores de tirosina cinasa de bruton | |
CY1124311T1 (el) | Παρεμποδιστες dna-pk | |
CL2016000468A1 (es) | Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso. | |
CY1120734T1 (el) | Στερεες μορφες ενος εκλεκτικου αναστολεα cdk4/6 | |
PH12014501815A1 (en) | Purinone compounds as kinase inhibitors | |
MX2020010412A (es) | Inhibidores de tirosina quinasa de bruton. | |
CL2016001604A1 (es) | “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct | |
CL2016000807A1 (es) | Amino heteroarilo benzamidas como inhibidores de quinasa. | |
NI201500062A (es) | Terapia adyuvante con inhibidores de quinasa de la familia tec | |
CR20150571A (es) | Compuestos y composiciones terapéuticos | |
CL2012002189A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos. | |
CL2014001865A1 (es) | Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer. | |
CL2013000016A1 (es) | Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer. | |
BR112015029386A8 (pt) | uso de eribulina e lenvatinibe como terapia de combinação, composição farmacêutica compreendendo os mesmos e kit | |
GT201500249A (es) | Terapia de combinación | |
EA201691032A1 (ru) | Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ | |
CL2011000168A1 (es) | Compuestos derivados de narciclasina y pancratistatina; procedimiento de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento del cáncer. | |
UY35823A (es) | Profármacos de antagonista de nmda | |
TW201613926A (en) | Inhibitors of bruton's tyrosine kinase | |
NI201200162A (es) | Inhibidores de pirazolil quinoxalina cinasa | |
UA110910C2 (uk) | Карбоксамідні похідні піразолу як інгібітори тирозинкінази брутона, фармацевтична композиція на їх основі та спосіб лікування захворювань (варіанти) | |
UY34131A (es) | Dosificación y administración de anticuerpos anti-erbb3 en combinación con inhibidores de tirosina quinasa. |